生殖支原体核酸半定量与分子大环内酯耐药检测:性别与标本来源考量
结果显示MRM检出率随TMA滴度升高而增加,且因性别和标本来源而异,支持对原始阳性标本进行耐药反射检测。
要点
- MRM-LDT检出率在TMA滴度≥4 log10时为88.7%,显著高于≤1 log10的4.5%。
- 女性阴道拭子MRM阳性率51.3%高于尿液的34.7%;男性直肠拭子65.0%高于尿液的55.7%。
- 男性标本平均TMA滴度3.67 log10高于女性的2.98 log10。
核心结论
- 生殖支原体大环内酯耐药率在美国多标本来源中较高,且与原始标本中靶核酸载量相关。
主要发现
- TMA阳性标本平均log10滴度为3.51(中位数3,范围0-10)。
- 男性标本(n=1145)平均log10滴度3.67,女性标本(n=350)为2.98(P < 0.0001)。
- MRM-LDT检出率在log10滴度≥4的标本为88.7%,在≤1的标本为4.5%(P < 0.0002)。
- 女性阴道拭子MRM阳性率51.3%,尿液34.7%(P = 0.01);男性直肠拭子65.0%,尿液55.7%(P = 0.002)。
关键数值与推荐
- MRM-LDT检出率:log10滴度≥4标本88.7%,≤1标本4.5%(P < 0.0002)。
- 女性阴道拭子MRM阳性率51.3%,尿液34.7%(P = 0.01)。
- 男性直肠拭子MRM阳性率65.0%,尿液55.7%(P = 0.002)。
临床怎么用
- 对生殖支原体TMA阳性原始标本进行MRM反射检测,以指导大环内酯类药物的治疗决策。
- 选择标本时应考虑性别和标本来源对耐药突变检出率的影响。
局限性
- 亚组分析中存在注意事项,支持对原始阳性标本进行MRM反射检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: A laboratory-developed test (LDT) using analyte-specific reagents has been optimized on a commercial platform to detect macrolide resistance-associated mutations (MRM) in 23S rRNA from Mycoplasmoides genitalium from primary clinical specimens. In this study, MRM-LDT was applied to a multi-specimen source study set. One thousand four hundred ninety-five primary specimens testing positive for M. genitalium by commercial transcription-mediated amplification (TMA) were initially titered by the TMA assay using serial 10-fold dilutions to semi-quantitate target nucleic acid burden. Primary specimens were then processed for MRM detection using the MRM-LDT. Findings were stratified by gender and specimen source. The mean log10 target nucleic acid titer of a TMA-positive specimen was 3.51 (median 3; range 0-10). Male specimens (n = 1145) demonstrated a mean log10 M. genitalium TMA titer of 3.67; that value observed in 350 female specimens was 2.98 (P < 0.0001). The MRM-LDT detection rate (88.7%) from specimens with log10 M. genitalium TMA titers ≥ 4 was increased over specimens with log10 titers ≤ 1 (4.5%; P < 0.0002). In females, MRM-LDT was positive from 51.3% of vaginal swab and 34.7% of urine specimens (P = 0.01). In males, MRM-LDT was positive from 65.0% of rectal swab and 55.7% of urine specimens (P = 0.002). Differences were also observed in log10 M. genitalium TMA titers as a function of specimen source. M. genitalium macrolide resistance rates among multiple specimen sources, as determined by MRM-LDT, are high in the United States and can be consistent with target nucleic acid burden within the primary specimen. Caveats experienced within subgroupings support MRM reflex testing on primary M. genitalium-positive specimens. IMPORTANCE: First-line macrolide treatment failure is of increasing concern with Mycoplasmoides genitalium in multiple settings. Recent sexually-transmitted infection treatment guidelines from the United States Centers for Disease Control and Prevention have predicated therapeutic approaches on the availability of a macrolide resistance/susceptibility result from a primary clinical specimen. In this report, we investigate potential correlation between macrolide resistance mutation detection rates (identified by a molecular amplified laboratory-developed test) and transcription-mediated amplification-based rRNA target semi-quantitation. Data reveal that rRNA semi-quantitation and laboratory-developed test detection rate differences exist as a function of gender and specimen source. These data can guide providers in proper specimen selection not only for the laboratory diagnosis of M. genitalium but also macrolide resistance mutation determination from primary clinical specimens.
引用
- Munson E, Moore J, Krueger T, et al. Mycoplasmoides genitalium nucleic acid semi-quantitation and molecular macrolide resistance detection via automated assays: gender and specimen source considerations. J Clin Microbiol. 2024. PMID: 38785449. doi:10.1128/jcm.00485-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。